Nxera Grants Pivlaz’s Korean Commercial Rights to Handok

April 16, 2024
Nxera Pharma, formerly known as Sosei Group, said on April 15 that it has awarded the exclusive commercial rights for Pivlaz (clazosentan) in South Korea to local partner Handok. The drug is scheduled for launch early next year. Nxera’s South...read more